Company profile
Shanghai Henlius Biotech
2696 · HKEX
Public Market Listing
2696HKEX
Live quotes, historical charts, and market capitalization for Shanghai Henlius Biotech are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(13 total)
13Total Assets
0Approved
7Phase 3 / Filed
6Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
HLX01No recent activity | Phase 3 | CD20Monoclonal antibody | Rheumatoid Arthritis |
| Phase 3 | VEGF-AMonoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration | |
| Phase 3 | EGFRMonoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | CD38Monoclonal antibody | Multiple Myeloma | |
| Phase 3 | PD-L1Antibody–drug conjugate | Non-Small Cell Lung CancerHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | BRAF V600ESmall molecule | Non-Small Cell Lung Cancer | |
| Phase 2 | BRAF V600E + PD-1 (combination regimen)Combination | Non-Small Cell Lung Cancer | |
| Phase 2 | LAG-3Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | PD-L1 / TIGITMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | EGFR x 4-1BB (CD137)Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | EGFRAntibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.